利巴韦林联合α干扰素、洛匹那韦/利托那韦联合α干扰素以及利巴韦林联合洛匹那韦/利托那韦联合α干扰素治疗轻度至中度2019新型冠状病毒病患者的疗效和安全性比较：研究方案 - Suppr

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.

作者信息

Zeng Yan-Ming, Xu Xiao-Lei, He Xiao-Qing, Tang Sheng-Quan, Li Yao, Huang Yin-Qiu, Harypursat Vijay, Chen Yao-Kai

机构信息

Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China.

National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing 400036, China.

出版信息

Chin Med J (Engl). 2020 May 5;133(9):1132-1134. doi: 10.1097/CM9.0000000000000790.

DOI:10.1097/CM9.0000000000000790

PMID:32149772

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7213617/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58db/7213617/8a2a47522553/cm9-133-1132-g001.jpg

相似文献

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.利巴韦林联合α干扰素、洛匹那韦/利托那韦联合α干扰素以及利巴韦林联合洛匹那韦/利托那韦联合α干扰素治疗轻度至中度2019新型冠状病毒病患者的疗效和安全性比较：研究方案

Chin Med J (Engl). 2020 May 5;133(9):1132-1134. doi: 10.1097/CM9.0000000000000790.

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.评价法维拉韦和干扰素与洛匹那韦/利托那韦和干扰素在 COVID-19 中度患者中的疗效和安全性：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Oct 27;21(1):886. doi: 10.1186/s13063-020-04747-8.

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.高剂量干扰素β-1a与低剂量干扰素β-1a（基础治疗方案）相比对中度至重度COVID-19的有益效果研究：一项随机对照试验研究方案的结构化总结

Trials. 2020 Oct 26;21(1):880. doi: 10.1186/s13063-020-04812-2.

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。

Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.

Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.停用抗病毒药物可能是新冠康复患者再次检测呈阳性的原因。

Br J Hosp Med (Lond). 2020 Apr 2;81(4):1-2. doi: 10.12968/hmed.2020.0156. Epub 2020 Apr 21.

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.五名重症新型冠状病毒肺炎患者接受了洛匹那韦/利托那韦、羟氯喹和干扰素β-1b三联疗法治疗。

Int J Antimicrob Agents. 2020 Aug;56(2):106052. doi: 10.1016/j.ijantimicag.2020.106052. Epub 2020 Jun 13.

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.回顾性多中心队列研究表明，早期干扰素治疗与 COVID-19 患者的良好临床反应相关。

Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2. doi: 10.1016/j.chom.2020.07.005. Epub 2020 Jul 18.

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.新型冠状病毒病治疗药物的研究进展。

Pharmacotherapy. 2020 May;40(5):416-437. doi: 10.1002/phar.2398. Epub 2020 May 6.

引用本文的文献

Advancements in the development of antivirals against SARS-Coronavirus.抗SARS冠状病毒抗病毒药物的研发进展。

Front Cell Infect Microbiol. 2025 Jan 23;15:1520811. doi: 10.3389/fcimb.2025.1520811. eCollection 2025.

COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people.新冠病毒疾病疫苗在机构养老老人中3个月时的安全性和有效性

BMC Geriatr. 2024 Dec 23;24(1):1032. doi: 10.1186/s12877-024-05609-7.

The relationship between oxygen therapy, drug therapy, and COVID-19 mortality.氧疗、药物治疗与新冠病毒病死亡率之间的关系。

Open Med (Wars). 2022 Nov 22;17(1):1833-1839. doi: 10.1515/med-2022-0569. eCollection 2022.

Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP).新型冠状病毒肺炎与猫传染性腹膜炎（FIP）的临床和分子关系。

Viruses. 2022 Feb 26;14(3):481. doi: 10.3390/v14030481.

Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2.挖掘抗凝剂针对 SARS-CoV-2 的宿主靶向交叉保护功效。

Pharmacol Ther. 2022 May;233:108027. doi: 10.1016/j.pharmthera.2021.108027. Epub 2021 Oct 28.

A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing.一种用于为新型冠状病毒SARS-CoV-2优先选择抗病毒药物以进行COVID-19药物再利用的深度学习集成方法。

Appl Soft Comput. 2021 Dec;113:107945. doi: 10.1016/j.asoc.2021.107945. Epub 2021 Oct 6.

Current status of traditional Chinese medicine for the treatment of COVID-19 in China.中国中医药治疗新型冠状病毒肺炎的现状

Chin Med. 2021 Jul 27;16(1):63. doi: 10.1186/s13020-021-00461-y.

Baidu Jieduan granules, traditional Chinese medicine, in the treatment of moderate coronavirus disease-2019 (COVID-19): study protocol for an open-label, randomized controlled clinical trial.百度截冠颗粒，中药，在治疗中度 2019 冠状病毒病（COVID-19）中的应用：一项开放标签、随机对照临床试验的研究方案。

Trials. 2021 Jul 22;22(1):476. doi: 10.1186/s13063-021-05418-y.

Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略

Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.

A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.一种计算方法，帮助临床医生在 COVID-19 试验中选择抗病毒药物。

Sci Rep. 2021 Apr 27;11(1):9047. doi: 10.1038/s41598-021-88153-3.

本文引用的文献

Protocol for Prevention and Control of COVID-19 (Edition 6).新型冠状病毒肺炎防控方案（第六版）

China CDC Wkly. 2020 May 8;2(19):321-326. doi: 10.46234/ccdcw2020.082.

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.洛匹那韦/利托那韦、利巴韦林和α干扰素联合治疗中东呼吸综合征

Antivir Ther. 2016;21(5):455-9. doi: 10.3851/IMP3002. Epub 2015 Oct 22.

Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.对近期一例接受三联抗病毒治疗方案的中东呼吸综合征冠状病毒感染病例进行的病毒学和血清学分析。

Int J Antimicrob Agents. 2014 Dec;44(6):528-32. doi: 10.1016/j.ijantimicag.2014.07.026. Epub 2014 Sep 18.

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China.中国广州严重急性呼吸综合征（SARS）早期暴发的描述及临床治疗

J Med Microbiol. 2003 Aug;52(Pt 8):715-720. doi: 10.1099/jmm.0.05320-0.

Development of a standard treatment protocol for severe acute respiratory syndrome.制定严重急性呼吸综合征的标准治疗方案。

Lancet. 2003 May 10;361(9369):1615-7. doi: 10.1016/s0140-6736(03)13265-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献